Home › Companies › RECURSION PHARMACEUTICALS INC. › 2023-2024
Compiled from SEC Form N-PX filings and RECURSION PHARMACEUTICALS INC.’s Form 8-K, filed June 7, 2024 (Item 5.07 on EDGAR). Page generated October 25, 2026.
Meeting of June 3, 2024: 3 items on RECURSION PHARMACEUTICALS INC.’s Form 8-K, filed June 7, 2024: 2 elected · 1 approved.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore RECURSION PHARMACEUTICALS INC. in the interactive database Compare manager voting policies
These tallies are RECURSION PHARMACEUTICALS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 7, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Blake Borgeson, Ph.D. | 165,914,956 | -- | -- | 26,093,759 | 0 | 86% | Elected | — |
| Elect Director: Dean Y. Li, M.D., Ph.D. | 166,211,058 | -- | -- | 25,797,657 | 0 | 87% | Elected | — |
| 2. Advisory resolution to approve executive compensation, as disclosed in the Proxy Statement | 188,317,831 | 2,887,180 | 803,704 | -- | 0 | 98% | Approved | — |
Source: RECURSION PHARMACEUTICALS INC., Form 8-K, filed with the SEC on June 7, 2024 — read the filing on EDGAR.
Each item below shows how the 224 asset managers that disclosed a RECURSION PHARMACEUTICALS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of RECURSION PHARMACEUTICALS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 4 wordings of this item as funds reported it.
86% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Blake Borgeson, Ph.D.
RECURSION PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Blake Borgeson, Ph.D.”): 165,914,956 for, 26,093,759 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, the Company's stockholders voted on the following proposals, each of which is described in more detail in the Company's definitive Proxy Statement for the Annual Meeting filed with the Securities and Exchange Commission on April 23, 2024 (the "Proxy Statement"): Proposal 1: T…”
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 59 asset managers below reported 8,788,626 for, 4,922,110 withheld, 117,681 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,991,528 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 1,214,217 | Withhold |
| BlackRock | 0 | 0 | 0 | 1,172,703 | Withhold |
| State Street | 837 | 0 | 0 | 785,461 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 393,174 | Withhold |
| Fidelity | 150,174 | 0 | 0 | 78,632 | Mixed |
| Lincoln Financial | 57,413 | 0 | 0 | 129,273 | Mixed |
| Nushares ETF Trust | 181,145 | 0 | 0 | 0 | For |
| Equitable | 0 | 0 | 0 | 157,852 | Withhold |
| ProShares | 0 | 0 | 0 | 148,460 | Withhold |
| WisdomTree | 129,041 | 0 | 0 | 0 | For |
| JPMorgan | 128,515 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 0 | 118,227 | Withhold |
| Dimensional | 0 | 0 | 0 | 99,793 | Withhold |
| First Trust | 0 | 0 | 0 | 95,521 | Withhold |
| Morgan Stanley | 0 | 0 | 0 | 79,722 | Withhold |
| Global X | 0 | 0 | 0 | 66,042 | Withhold |
| WESMARK FUNDS | 0 | 0 | 0 | 65,200 | Withhold |
| Northern Trust | 0 | 0 | 0 | 59,285 | Withhold |
| Bridge Builder Trust | 0 | 0 | 56,050 | 0 | Abstain |
| Pacific Life | 0 | 0 | 0 | 55,774 | Withhold |
| BAILLIE GIFFORD FUNDS | 48,012 | 0 | 0 | 0 | For |
| ARK Venture Fund | 44,310 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 30,835 | 0 | Abstain |
| ETF Series Solutions | 0 | 0 | 26,626 | 0 | Abstain |
Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.
Combines 4 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Dean Y. Li, M.D., Ph.D.
RECURSION PHARMACEUTICALS INC.’s own tally for this item (“Elect Director: Dean Y. Li, M.D., Ph.D.”): 166,211,058 for, 25,797,657 withheld, per its Form 8-K filed June 7, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “At the Annual Meeting, the Company's stockholders voted on the following proposals, each of which is described in more detail in the Company's definitive Proxy Statement for the Annual Meeting filed with the Securities and Exchange Commission on April 23, 2024 (the "Proxy Statement"): Proposal 1: T…”
Support: 87% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 59 asset managers below reported 8,879,763 for, 4,830,973 withheld, 117,681 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,991,528 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 1,214,217 | Withhold |
| BlackRock | 0 | 0 | 0 | 1,172,703 | Withhold |
| State Street | 837 | 0 | 0 | 785,461 | Withhold |
| Direxion Shares ETF Trust | 0 | 0 | 0 | 393,174 | Withhold |
| Fidelity | 150,174 | 0 | 0 | 78,632 | Mixed |
| Lincoln Financial | 57,413 | 0 | 0 | 129,273 | Mixed |
| Nushares ETF Trust | 181,145 | 0 | 0 | 0 | For |
| Equitable | 3,507 | 0 | 0 | 154,345 | Withhold |
| ProShares | 0 | 0 | 0 | 148,460 | Withhold |
| WisdomTree | 129,041 | 0 | 0 | 0 | For |
| JPMorgan | 128,515 | 0 | 0 | 0 | For |
| Voya | 0 | 0 | 0 | 118,227 | Withhold |
| Dimensional | 0 | 0 | 0 | 99,793 | Withhold |
| First Trust | 0 | 0 | 0 | 95,521 | Withhold |
| Morgan Stanley | 74,685 | 0 | 0 | 5,037 | Mixed |
| Global X | 0 | 0 | 0 | 66,042 | Withhold |
| WESMARK FUNDS | 0 | 0 | 0 | 65,200 | Withhold |
| Northern Trust | 0 | 0 | 0 | 59,285 | Withhold |
| Bridge Builder Trust | 0 | 0 | 56,050 | 0 | Abstain |
| Pacific Life | 0 | 0 | 0 | 55,774 | Withhold |
| BAILLIE GIFFORD FUNDS | 48,012 | 0 | 0 | 0 | For |
| ARK Venture Fund | 44,310 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 30,835 | 0 | Abstain |
| ETF Series Solutions | 0 | 0 | 26,626 | 0 | Abstain |
Showing the 25 largest of 59 asset managers. See all 59 in the interactive database.
Combines 4 wordings of this item as funds reported it.
67% of fund votes cast · no official result
The 20 asset managers below reported 2,623,747 for, 1,294,842 withheld, 303,609 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 2,484,830 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 1,214,217 | Withhold |
| JPMorgan | 0 | 0 | 128,515 | 0 | Abstain |
| Global X | 0 | 0 | 0 | 66,042 | Withhold |
| Lincoln Financial | 0 | 0 | 57,413 | 0 | Abstain |
| Bridge Builder Trust | 0 | 0 | 56,050 | 0 | Abstain |
| BAILLIE GIFFORD FUNDS | 48,012 | 0 | 0 | 0 | For |
| ARK Venture Fund | 44,310 | 0 | 0 | 0 | For |
| John Hancock | 0 | 0 | 30,835 | 0 | Abstain |
| ETF Series Solutions | 0 | 0 | 26,626 | 0 | Abstain |
| AMERICAN BEACON FUNDS | 24,998 | 0 | 0 | 0 | For |
| TARGET PORTFOLIO TRUST | 20,700 | 0 | 0 | 0 | For |
| NEW COVENANT FUNDS | 0 | 0 | 0 | 11,559 | Withhold |
| Allianz | 0 | 0 | 4,160 | 0 | Abstain |
| Russell Investments | 0 | 0 | 0 | 1,274 | Withhold |
| Nationwide | 0 | 0 | 0 | 1,150 | Withhold |
| SEI | 0 | 0 | 0 | 600 | Withhold |
| Advisors' Inner Circle Fund III | 473 | 0 | 0 | 0 | For |
| Pacer Funds Trust | 424 | 0 | 0 | 0 | For |
| WILSHIRE MUTUAL FUNDS INC | 0 | 0 | 10 | 0 | Abstain |
— of fund votes cast · no official result
The 4 asset managers below reported 14,473 not voted, 763 unknown.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Lincoln Financial | 0 | 0 | 0 | 0 | Not Voted |
| Humankind Benefit Corp | 0 | 0 | 0 | 0 | -- |
| Blackstone Alternative Investment Funds | 0 | 0 | 0 | 0 | Not Voted |
| SA FUNDS INVESTMENT TRUST | 0 | 0 | 0 | 0 | -- |
Combines 8 wordings of this item as funds reported it.
98% Approved · of votes cast
Description as filed by funds: ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION AS DISCLOSED IN THE 2024 PROXY STATEMENT.
RECURSION PHARMACEUTICALS INC.’s own tally for this item (“2. Advisory resolution to approve executive compensation, as disclosed in the Proxy Statement”): 188,317,831 for, 2,887,180 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2: The advisory resolution to approve executive compensation, as disclosed in the Proxy Statement, was approved, with the following votes cast:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,991,528 | 0 | 0 | 0 | For |
| Charles Schwab | 1,214,217 | 0 | 0 | 0 | For |
| BlackRock | 1,172,703 | 0 | 0 | 0 | For |
| State Street | 786,298 | 0 | 0 | 0 | For |
| Direxion Shares ETF Trust | 393,174 | 0 | 0 | 0 | For |
| Fidelity | 228,806 | 0 | 0 | 0 | For |
| Lincoln Financial | 186,686 | 0 | 0 | 0 | For |
| Nushares ETF Trust | 181,145 | 0 | 0 | 0 | For |
| Equitable | 157,852 | 0 | 0 | 0 | For |
| ProShares | 148,460 | 0 | 0 | 0 | For |
| WisdomTree | 129,041 | 0 | 0 | 0 | For |
| JPMorgan | 128,515 | 0 | 0 | 0 | For |
| Voya | 118,227 | 0 | 0 | 0 | For |
| Dimensional | 99,793 | 0 | 0 | 0 | For |
| First Trust | 95,521 | 0 | 0 | 0 | For |
| Morgan Stanley | 79,722 | 0 | 0 | 0 | For |
| Global X | 66,042 | 0 | 0 | 0 | For |
| WESMARK FUNDS | 65,200 | 0 | 0 | 0 | For |
| Northern Trust | 59,285 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 56,050 | 0 | 0 | 0 | For |
| Pacific Life | 55,774 | 0 | 0 | 0 | For |
| BAILLIE GIFFORD FUNDS | 48,012 | 0 | 0 | 0 | For |
| ARK Venture Fund | 44,310 | 0 | 0 | 0 | For |
| John Hancock | 30,835 | 0 | 0 | 0 | For |
| Investment Managers Series Trust II | 26,859 | 0 | 0 | 0 | For |
Fund voting reports, all 59 managers: 13,841,387 for, 13,889 against. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| BAILLIE GIFFORD & CO LTD | 18,866,091 | 0 | 0 | 0 | For |
| Nikko Asset Management Americas, Inc. | 8,909,455 | 0 | 0 | 0 | For |
| BAILLIE GIFFORD OVERSEAS LTD | 2,591,820 | 0 | 0 | 0 | For |
| Lingotto Investment Management LLP | 2,175,077 | 0 | 0 | 0 | For |
| State Street | 2,163,341 | 0 | 0 | 0 | For |
| UBS | 0 | 1,618,914 | 0 | 0 | Against |
| BlackRock | 1,576,539 | 0 | 0 | 0 | For |
| PLATINUM INVESTMENT MANAGEMENT LTD | 1,570,614 | 0 | 0 | 0 | For |
| Nikko Asset Management Co., Ltd. | 1,403,642 | 0 | 0 | 0 | For |
| MIC Capital Management UK LLP | 1,388,889 | 0 | 0 | 0 | For |
| Charles Schwab | 1,214,217 | 0 | 0 | 0 | For |
| Liontrust Investment Partners LLP | 872,449 | 0 | 0 | 0 | For |
| Vestmark Advisory Solutions, Inc. | 728,095 | 0 | 0 | 0 | For |
| Northern Trust | 686,233 | 93 | 0 | 0 | For |
| Cercano Management LLC | 685,018 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 398,936 | 0 | 0 | 0 | For |
| Rafferty Asset Management, LLC | 393,174 | 0 | 0 | 0 | For |
| Lazard | 373,163 | 0 | 0 | 0 | For |
| Fidelity | 365,046 | 0 | 0 | 0 | For |
| Sculptor Capital II LP | 318,400 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 292,812 | 0 | 0 | 0 | For |
| Mitsubishi UFJ Trust & Banking Corp | 270,360 | 0 | 0 | 0 | For |
| Nuveen | 196,151 | 0 | 0 | 0 | For |
| Morgan Stanley | 188,140 | 0 | 0 | 0 | For |
| Goldman Sachs | 156,659 | 0 | 0 | 0 | For |
Institutional-manager reports, all 179 managers: 49,955,070 for, 1,959,593 against, 12,121 not voted. Showing the 25 largest; see all in the interactive database.
98% Approved · of votes cast
Description as filed by funds: Advisory Vote to Ratify Named Executive Officers' Compensation
RECURSION PHARMACEUTICALS INC.’s own tally for this item (“2. Advisory resolution to approve executive compensation, as disclosed in the Proxy Statement”): 188,317,831 for, 2,887,180 against — passed, per its Form 8-K filed June 7, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2: The advisory resolution to approve executive compensation, as disclosed in the Proxy Statement, was approved, with the following votes cast:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 3 asset managers below reported 518,692 for, 1,747 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| JPMorgan | 518,592 | 0 | 0 | 0 | For |
| Desjardins Global Asset Management Inc. | 0 | 1,747 | 0 | 0 | Against |
| TD ASSET MANAGEMENT INC | 100 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 237,508,682 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 3.36% |
| 2 | Charles Schwab | 0.51% |
| 3 | BlackRock | 0.49% |
| 4 | State Street | 0.33% |
| 5 | Direxion Shares ETF Trust | 0.17% |
| 6 | Fidelity | 0.10% |
| 7 | Lincoln Financial | 0.08% |
| 8 | Nushares ETF Trust | 0.08% |
| 9 | Equitable | 0.07% |
| 10 | ProShares | 0.06% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | BAILLIE GIFFORD & CO LTD | 7.94% |
| 2 | Nikko Asset Management Americas, Inc. | 3.75% |
| 3 | BAILLIE GIFFORD OVERSEAS LTD | 1.09% |
| 4 | Lingotto Investment Management LLP | 0.92% |
| 5 | State Street | 0.91% |
| 6 | UBS | 0.68% |
| 7 | BlackRock | 0.66% |
| 8 | PLATINUM INVESTMENT MANAGEMENT LTD | 0.66% |
| 9 | Nikko Asset Management Co., Ltd. | 0.59% |
| 10 | MIC Capital Management UK LLP | 0.58% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| Vanguard Group | 16.75% | 13F |
| BlackRock | 13.36% | 13F |
| Baillie Gifford & Co | 10.18% | DEF14A |
| ARK Investment Management LLC | 9.72% | 13G |
| MDC Capital Partners | 8.44% | DEF14A |
| Zachary Bogue | 5.74% | DEF14A |
| DCVC | 5.73% | DEF14A |
| FMR LLC | 4.59% | DEF14A |
| Kinnevik AB | 4.38% | DEF14A |
| State Street | 4.36% | 13F |
Percentages above are of 237,508,682 shares outstanding, as reported by RECURSION PHARMACEUTICALS INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from RECURSION PHARMACEUTICALS INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on October 25, 2026; a live search always shows the current data.
At RECURSION PHARMACEUTICALS INC.'s shareholder meeting held June 3, 2024, in the 2023-2024 proxy season, 224 asset managers reported how they voted in their SEC Form N-PX filings, covering 868 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — ADVISORY VOTE TO APPROVE EXECUTIVE COMPENSATION AS DISCLOSED IN THE 2024 PROXY STATEMENT. — RECURSION PHARMACEUTICALS INC.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: RECURSION PHARMACEUTICALS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 7, 2024.
RECURSION PHARMACEUTICALS INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Download data (CSV): ballot items · votes by manager · column guide.